DCGODocGo Inc. Common Stock

0.4345USD+3.33%Mkt Cap: 42.98M $P/E:

DocGo Inc. operates as a mobile healthcare services company in the United States and the United Kingdom. It operates through Mobile Health Services and Transportation Services segments. The company offers transportation …

HeadlineSourceTime
Older
DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic Hicuity ...

DocGo Inc (DCGO) reports 19% ex-migrant revenue growth and record medical transportation volumes, while navigating margin pressures and a transformative acquisition.

GuruFocus.com
DocGo Inc. Q2 2026 Earnings Call Summary

Moby summary of DocGo Inc.'s Q2 2026 earnings call

Moby
DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

DocGo (NASDAQ:DCGO) shares fell sharply in pre-market trading on Tuesday after the mobile healthcare and medical transportation provider reported weaker-than-expected second-quarter 2026 results and significantly increased its projected full-year adjusted EBITDA loss. The stock dropped 12.

InvestorsHub
DocGo Q2 Earnings Call Highlights

DocGo (NASDAQ:DCGO) reported second-quarter revenue of $73.4 million, down from $80.4 million a year earlier, as the company continued to wind down migrant-related projects. Excluding migrant-related revenue, revenue rose 19% year over year, while revenue from business lines operating in both period

MarketBeat
DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates

Motion Acquisition (DCGO) delivered earnings and revenue surprises of +500.00% and -2.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates

Lifeward (LFWD) delivered earnings and revenue surprises of +2.01% and -10.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +71.43% and +45.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Strength Seen in Surgery Partners (SGRY): Can Its 5.3% Jump Turn into More Strength?

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks